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Glucagon like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) for the treatment of Type 2 Diabetes 
(T2DM) were first introduced to Europe and the USA in 2005(1) . Since then, they  have become  
well-established treatment options in the management  of T2DM(2). GLP-1 RAs have several 
attractive features including: potent and sustained glucose lowering, low risk of hypoglycaemia due to 
their glucose-dependent effects on insulin and glucagon secretion, sustained weight-loss, and a 
favourable impact on cardiovascular risk factors together with reduction in cardiovascular event rates 
(liraglutide and semaglutide)(1;3-5). Several injectable GLP-1 RAs are now licensed for the treatment 
of T2DM, and other approaches including oral and continuous delivery via an osmotic mini-pump are 
in development(1;6;7), offering patients a range of dosing and delivery regimens. Together, the 
clinical attributes and delivery options may be very attractive to patients and health care professionals 
(HCPs) with the potential to reduce clinical inertia, improve therapy adherence and achieve sustained  
glycaemic control(8). On the other hand, the intra-class differences in the pharmacokinetic and 
pharmacodynamic properties of these agents raises challenges in terms of individualising treatment. 
Hence, there is a need for head-to-head trials comparing the efficacy, safety and acceptability of GLP-
1 RAs(9). 
In this issue of the Journal, Pratley et al present their findings from SUSTAIN 7, a multi-centre, 
randomised, open-label, phase 3b trial of two once weekly GLP-1 RAs, semaglutide vs. dulaglutide, 
in patients with T2DM inadequately controlled with metformin (REF TO BE INSERTED). Over 40 
weeks, whilst both agents showed good glycaemic efficacy, semaglutide was superior to dulaglutide 
in terms of the HbA1c -lowering and weight loss despite the higher use of rescue treatment in the 
latter group. In addition, more patients randomised to semaglutide achieved the composite secondary 
outcome of HbA1c <7·0% (53 mmol/mol) without severe or confirmed symptomatic hypoglycaemia 
and no weight gain compared with dulaglutide.  
Superior clinical efficacy, however, should always be considered in the context of safety. The adverse 
events profiles were largely comparable between the two agents and consistent with expectations from 
the class.  Premature treatment discontinuation, however, occurred more frequently with semaglutide, 
mostly due to gastrointestinal side effects. Nonetheless, treatment discontinuation was uncommon 
affecting < 10% of patients. Diabetic retinopathy (DR) is another important safety concern in the light 
of  results from  SUSTAIN 6(5). The current study shows no evidence for increased risk of 
progression of DR with semaglutide, but the SUSTAIN 6 population were at higher cardiovascular 
risk and patients with proliferative DR or maculopathy were excluded from SUSTAIN 7. There is still 
a need, therefore, for further data regarding the effects of semaglutide on DR.  
Differences in efficacy between  GLP-1 RAs have been observed in several head-to-head trials(9) 
without clear explanations. Efficacy differences  in the current trial could be due, at least in part, to 
differences in the structure and  size of  semaglutide (a GLP-1 analogue with a fatty diacid chain) and 
dulaglutide (two copies of a GLP-1 analogue with amino acid substitutions Ala8Gly, Gly22Glu and 
Arg36Gly, covalently linked to an Fc fragment of human IgG4) molecules(1). This might result in a 
differential ability of the GLP-1 RA to reach the appetite control centres in the brain and hence 
provoke differences in weight loss, leading to differences in the glucose lowering efficacy of these 
two molecules.  However, this hypothesis needs to be tested and the current study does not explore 
whether the greater weight loss with  semaglutide is  responsible for the greater HbA1c reductions  in 
the semaglutide arm. 
 Mode and ease of drug delivery (particularly in the context of injectables) are important factors in the 
context of treatment acceptability and adherence. The present trial delivered both study drugs using 
their respective licensed devices. Comparing patient views on usability and acceptability of the 
injection devices, however, was not part of the study design, although measures of treatment 
satisfaction and quality of life showed no differences between semaglutide and dulaglutide. Future 
studies should examine patient preferences in terms of the devices used as this might have 
implications in real life. 
When choosing the “next” glucose lowering agent in patients with T2DM, HCPs need to consider 
multiple factors in addition to glycaemic efficacy in order to personalise treatment approaches based 
on individualised treatment targets. Such factors may include the impact on weight, hypoglycaemia, 
cardiovascular risk, diabetes-related complications, tolerability, ease of use, durability of effects,  
interactions with other agents, patients age and renal and/or hepatic impairment. Whilst 2 head to head 
trials of semaglutide versus other weekly GLP-1 RAs (the current trial and SUSTAIN 3)(10) 
demonstrate glycaemia and weight advantages of semaglutide, treatment decisions should allow for 
differences in trial designs and the generalisability of the findings in a real life setting. For example, 
the SUSTAIN 7  findings apply to patients who were only on metformin and who were at relatively 
low cardiovascular risk since patients with renal impairment, established cardiovascular disease and 
advanced DR were excluded. In addition, much more information as to the relative utility within class 
of these agents from Real World settings is required to establish their true place in the management of 
T2DM.  
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